The cystic fibrosis lung microenvironment alters antibiotic activity: causes and effects
Chronic airway colonisation by Pseudomonas aeruginosa, a hallmark of cystic fibrosis (CF) lung disease, is associated with increased morbidity and mortality and despite aggressive antibiotic treatment, P. aeruginosa is able to persist in CF airways. In vitro antibiotic susceptibility assays are poor...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
European Respiratory Society
2021-09-01
|
Series: | European Respiratory Review |
Online Access: | http://err.ersjournals.com/content/30/161/210055.full |
id |
doaj-e2b055532f87459e9da091710c8351a4 |
---|---|
record_format |
Article |
spelling |
doaj-e2b055532f87459e9da091710c8351a42021-09-29T08:56:44ZengEuropean Respiratory SocietyEuropean Respiratory Review0905-91801600-06172021-09-013016110.1183/16000617.0055-20210055-2021The cystic fibrosis lung microenvironment alters antibiotic activity: causes and effectsSara Van den Bossche0Emma De Broe1Tom Coenye2Eva Van Braeckel3Aurélie Crabbé4 Laboratory of Pharmaceutical Microbiology, Ghent University, Ghent, Belgium Laboratory of Pharmaceutical Microbiology, Ghent University, Ghent, Belgium Laboratory of Pharmaceutical Microbiology, Ghent University, Ghent, Belgium Dept of Respiratory Medicine, Cystic Fibrosis Reference Centre, Ghent University Hospital, Ghent, Belgium Laboratory of Pharmaceutical Microbiology, Ghent University, Ghent, Belgium Chronic airway colonisation by Pseudomonas aeruginosa, a hallmark of cystic fibrosis (CF) lung disease, is associated with increased morbidity and mortality and despite aggressive antibiotic treatment, P. aeruginosa is able to persist in CF airways. In vitro antibiotic susceptibility assays are poor predictors of antibiotic efficacy to treat respiratory tract infections in the CF patient population and the selection of the antibiotic(s) is often made on an empirical base. In the current review, we discuss the factors that are responsible for the discrepancies between antibiotic activity in vitro and clinical efficacy in vivo. We describe how the CF lung microenvironment, shaped by host factors (such as iron, mucus, immune mediators and oxygen availability) and the microbiota, influences antibiotic activity and varies widely between patients. A better understanding of the CF microenvironment and population diversity may thus help improve in vitro antibiotic susceptibility testing and clinical decision making, in turn increasing the success rate of antibiotic treatment.http://err.ersjournals.com/content/30/161/210055.full |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sara Van den Bossche Emma De Broe Tom Coenye Eva Van Braeckel Aurélie Crabbé |
spellingShingle |
Sara Van den Bossche Emma De Broe Tom Coenye Eva Van Braeckel Aurélie Crabbé The cystic fibrosis lung microenvironment alters antibiotic activity: causes and effects European Respiratory Review |
author_facet |
Sara Van den Bossche Emma De Broe Tom Coenye Eva Van Braeckel Aurélie Crabbé |
author_sort |
Sara Van den Bossche |
title |
The cystic fibrosis lung microenvironment alters antibiotic activity: causes and effects |
title_short |
The cystic fibrosis lung microenvironment alters antibiotic activity: causes and effects |
title_full |
The cystic fibrosis lung microenvironment alters antibiotic activity: causes and effects |
title_fullStr |
The cystic fibrosis lung microenvironment alters antibiotic activity: causes and effects |
title_full_unstemmed |
The cystic fibrosis lung microenvironment alters antibiotic activity: causes and effects |
title_sort |
cystic fibrosis lung microenvironment alters antibiotic activity: causes and effects |
publisher |
European Respiratory Society |
series |
European Respiratory Review |
issn |
0905-9180 1600-0617 |
publishDate |
2021-09-01 |
description |
Chronic airway colonisation by Pseudomonas aeruginosa, a hallmark of cystic fibrosis (CF) lung disease, is associated with increased morbidity and mortality and despite aggressive antibiotic treatment, P. aeruginosa is able to persist in CF airways. In vitro antibiotic susceptibility assays are poor predictors of antibiotic efficacy to treat respiratory tract infections in the CF patient population and the selection of the antibiotic(s) is often made on an empirical base. In the current review, we discuss the factors that are responsible for the discrepancies between antibiotic activity in vitro and clinical efficacy in vivo. We describe how the CF lung microenvironment, shaped by host factors (such as iron, mucus, immune mediators and oxygen availability) and the microbiota, influences antibiotic activity and varies widely between patients. A better understanding of the CF microenvironment and population diversity may thus help improve in vitro antibiotic susceptibility testing and clinical decision making, in turn increasing the success rate of antibiotic treatment. |
url |
http://err.ersjournals.com/content/30/161/210055.full |
work_keys_str_mv |
AT saravandenbossche thecysticfibrosislungmicroenvironmentaltersantibioticactivitycausesandeffects AT emmadebroe thecysticfibrosislungmicroenvironmentaltersantibioticactivitycausesandeffects AT tomcoenye thecysticfibrosislungmicroenvironmentaltersantibioticactivitycausesandeffects AT evavanbraeckel thecysticfibrosislungmicroenvironmentaltersantibioticactivitycausesandeffects AT aureliecrabbe thecysticfibrosislungmicroenvironmentaltersantibioticactivitycausesandeffects AT saravandenbossche cysticfibrosislungmicroenvironmentaltersantibioticactivitycausesandeffects AT emmadebroe cysticfibrosislungmicroenvironmentaltersantibioticactivitycausesandeffects AT tomcoenye cysticfibrosislungmicroenvironmentaltersantibioticactivitycausesandeffects AT evavanbraeckel cysticfibrosislungmicroenvironmentaltersantibioticactivitycausesandeffects AT aureliecrabbe cysticfibrosislungmicroenvironmentaltersantibioticactivitycausesandeffects |
_version_ |
1716864507981070337 |